UBS Maintains Buy on Privia Health Gr, Lowers Price Target to $32
Portfolio Pulse from richadhand@benzinga.com
UBS analyst Andrew Mok maintains a Buy rating on Privia Health Gr (NASDAQ:PRVA) but lowers the price target from $35 to $32.
August 18, 2023 | 1:17 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
UBS analyst Andrew Mok maintains a Buy rating on Privia Health Gr but lowers the price target from $35 to $32.
The news is directly related to Privia Health Gr (PRVA). The maintained Buy rating indicates a positive outlook for the company, however, the lowered price target may indicate a slightly less optimistic view on the company's future performance. This could potentially have a neutral impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100